Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.34 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenylacetylene SCHEMBL28395897 | 0.97 | APP (0.41) | APPHDAC8TSHRPTPN1CYP2C9 | |
| Phenylacetylene SCHEMBL4884 | 0.88 | — | — | |
| Phenylacetylene SCHEMBL4297769 | 0.88 | — | — | |
| Phenylacetylene SCHEMBL27795197 | 0.88 | APP (0.53) | APPHDAC8TSHRPTPN1CYP2C9 | |
| Phenylacetylene SCHEMBL1331398 | 0.88 | — | — | |
| Phenylacetylene SCHEMBL6891916 | 0.88 | APP (0.53) | APPHDAC8TSHRPTPN1CYP2C9 | |
| Phenylacetylene SCHEMBL1331558 | 0.88 | — | — | |
| Phenylacetylene SCHEMBL1331408 | 0.88 | — | — | |
| Biphenyl SCHEMBL28621540 | 0.86 | ALDH1A1 (0.53) | APPHDAC8TSHRCYP2C9ALDH1A1 | |
| Phenylacetylene SCHEMBL28273554 | 0.86 | HDAC8 (0.46) | APPHDAC8TSHRPTPN1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| US-9908819-B1 | Printing method for production a ceramic green body | WZR ceramic solutions GmbH (DE) | 2018-03-06 | — | — | US | disclosed |
| US-20060100465-A1 | METHOD FOR HALOGENATING OR RADIOHALOGENATING A CHEMICAL COMPOUND | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2006-05-11 | — | — | US | disclosed |
| US-7041859-B1 | Method for halogenating or radiohalogenating a chemical compound | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2006-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100465-A1 | METHOD FOR HALOGENATING OR RADIOHALOGENATING A CHEMICAL COMPOUND | AOX1, TPO, LPO | APP 4097/4885HDAC8 1848/4885TSHR 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.